Medeze Group (MEDEZE.BK) Stock Price

Medeze Group Price

CLOSED
6.05
​
Market closed

Revenue has compounded at 15.9% per year over the past 8 years to 743.65 M THB. Earnings per share have declined at 10.6% per year over the last 8 years. Medeze Group's net margin stands at 26.4%, broadly stable from 26.3% several years earlier. Medeze Group currently offers a dividend yield of about 2.64%. The payout ratio is around 87% of earnings.

Medeze Group stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medeze Group business model & stock analysis

Medeze Group PLC is a TH-based company operating in industry. The company is headquartered in Nakhon Pathom, Nakhon Pathom. The company went IPO on 2024-10-15. Medeze Group Plc is a Thailand-based company operating as a mesenchymal stem cell bank. The company offers stem cell storage services from umbilical cord tissue and adipose tissue, in addition to the storage of umbilical cord blood. The company is engaged in providing stem cell analysis, separation, cultivation and storage services and provide immune cell potential testing services with biotechnology. Its stem cell sample collection service segment provides collection and storage services, sorting, cultivation and development of stem cells. Its white blood cell potential testing service segment offers potential testing services that evaluate the performance and count the number of Natural killer cells (NK cells). Its other services segment provides other services, such as research services, develop and collect data on all types of human cellular activities and medical laboratory test. Its sales of products segment provide sales of dietary supplements, cosmetics, and dermo cosmetics.

Frequently asked questions about Medeze Group

Converted at the current exchange rate, the Medeze Group share trades at 0.16 EUR (6.05 THB).

The expected revenue of Medeze Group is 698.50 M THB. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Medeze Group is 234.96 M THB. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Medeze Group is currently 27.50. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Medeze Group stock.

The price-to-sales ratio (P/S) of Medeze Group is currently 9.25. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Medeze Group stock.

The Eulerpool Quality Score for Medeze Group is 3/10.

The ISIN of Medeze Group is THC430010007. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Medeze Group is MEDEZE.BK. The ticker symbol is used to trade Medeze Group shares on the stock exchange.

Fair ValueTerminal
6.29 THB
Over-/UndervaluationTerminal
Fairly valued
Sector
—
Industry
Other
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Thailand
Currency
THB
Initial public offering
Oct 15, 2024
ISIN
THC430010007
Cusip
Y5942A118
Market capitalization
6.46 B THBMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
27.50
P/Ee 2027
18.15
P/S
P/Se
9.25
EV/EBIT
28.30
P/B Ratio
2.22
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
6.74 %
Last updated Oct 15, 2026, 11:30 PM

Medeze Group Peer Group